Though money is flowing more freely into the biotech sector these days, one consequence of the financial turmoil of recent years has been that it’s forced companies to think more broadly about their funding sources. At the same time, a greater emphasis on translational research and increased funding to the National Institutes of Health is creating greater opportunities for companies. We spoke to Ram May-Ron, vice president of the Boston-based FreeMind Group, which specializes in helping companies raise money from government agencies through grants and contracts, about the opportunities for life sciences companies to get government funding today, how such grants fit into a broader funding strategy and why he’s been disappointed in the stimulus package so far.